On World Diabetes Day, it's worth taking a look back at the last 10.5 months in the diabetes technology space.

Insulet’s Omnipod 5 automated insulin delivery (AID) system has multiple avenues to expand as it has revolutionized the way patients treat their diabetes, including the new indication for Type 2 ...

Kamen and Sequel Medtech CEO Alan Lotvin say they are offering greater precision in insulin delivery with new pump technology ...

The S&P 500 added 0.4% on Friday, Nov. 8, posting its highest-ever close to end a momentous week that included an election ...

Revenue grew 26% to $543.9 million, ahead of the $519.5 that analysts forecast. Chief Executive Jim Hollingshead said the company's Omnipod 5 automated insulin delivery system -- which was cleared by ...

Insulet saw strong insulin pump adoption among new users with Type 2 diabetes following its recent FDA clearance, while ...

PLYMOUTH MEETING, Pa. – AdaptHealth CEO Suzanne Foster is doubling down on efforts to turn around the company’s struggling diabetes business, saying it was “worse” than she initially thought it was.

The company now expects its annual 2024 revenue to grow between 20% and 21%, up from its previous forecast of 16% to 19% ...

Insulet ( (PODD) ) has released its Q3 earnings. Here is a breakdown of the information Insulet presented to its investors. Insulet ...

Reports Q3 revenue $543.9M, consensus $518.26M. “We continue to achieve significant milestones and robust revenue growth,” said Jim ...

CNW/ - Ypsomed and CamDiab are pleased to announce the approval of mylife YpsoPump insulin pump and CamAPS FX hybrid closed-loop algorithm by Health Canada. This approval represents an important step ...

Insulet (Nasdaq:PODD) shares ticked up today on third-quarter results that came in well ahead of the consensus forecast.